Wechselwirkungen von Naltrexon

Naltrexon (Vivitrol, Revia), ein Opioidantagonist, hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 77 dokumentierte Wechselwirkungen: 40 schwerwiegende, 3 mittelschwere, 31 geringfügige und 3, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.

Wechselwirkungen laut Fachinformation

Schwerwiegende Wechselwirkungen (40)

  • Belladonna und OpiumOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • Bictegravir, Emtricitabin und Tenofoviralafenamidantiretrovirales ArzneimittelSchwerwiegend

    Opioid Antagonist: Naloxegol ↑ naloxegol Avoid use with BIXLENVO; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (Fachinformation zu Bictegravir, Emtricitabin und Tenofoviralafenamid, Arzneimittelwechselwirkungen)

  • BuprenorphinOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • Buprenorphin und NaloxonOpioidSchwerwiegend

    Any individual who has failed the naloxone challenge test or has a positive urine screen for opioids [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • ButorphanolOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • CodeinOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • Darunavirantiretrovirales ArzneimittelSchwerwiegend

    John's wort ( Hypericum perforatum ) Hepatitis C direct acting antiviral: elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir… (Fachinformation zu Darunavir, Gegenanzeigen)

  • Darunavir und Cobicistatantiretrovirales ArzneimittelSchwerwiegend

    John's wort ( Hypericum perforatum ) Hepatitis C direct acting antiviral: elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam PREZCOBIX or PREZCOBIX PED is… (Fachinformation zu Darunavir und Cobicistat, Gegenanzeigen)

  • EluxadolinOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • FentanylOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • HydrocodonOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • Hydrocodon und ChlorphenaminOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • Hydrocodon und HomatropinOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • Hydrocodon und IbuprofenOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • Hydrocodon und ParacetamolOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • HydromorphonOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • Lenacapavirantiretrovirales ArzneimittelSchwerwiegend

    Opioid Antagonist: naloxegol ↑ naloxegol Avoid use with SUNLENCA; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (Fachinformation zu Lenacapavir, Arzneimittelwechselwirkungen)

  • LevorphanolOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • MethadonOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • MethylnaltrexonOpioidantagonistSchwerwiegend

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (Fachinformation zu Methylnaltrexon, Arzneimittelwechselwirkungen)

  • MorphinOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • NalbuphinOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • NaldemedinOpioidantagonistSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • NaloxegolOpioidantagonistSchwerwiegend

    Other opioid antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (Fachinformation zu Naloxegol, Arzneimittelwechselwirkungen)

  • NaloxonOpioidantagonistSchwerwiegend

    Any individual who has failed the naloxone challenge test or has a positive urine screen for opioids [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • Nirmatrelvir und RitonavirVirostatikumSchwerwiegend

    …Migraine medications: eletriptan, ubrogepant • Mineralocorticoid receptor antagonists: finerenone • Non-opioid analgesic (selective blocker of Na v 1.8 sodium channels): suzetrigine • Opioid antagonists: naloxegol • PDE5 inhibitor: sildenafil (Revatio ® ) when used for pulmonary arterial hypertension (PAH) • Sedative/hypnotics: triazolam, oral midazolam • Serotonin… (Fachinformation zu Nirmatrelvir und Ritonavir, Gegenanzeigen)

  • OliceridinOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • OxycodonOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • Oxycodon und ParacetamolOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • OxymorphonOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • Paracetamol und CodeinOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • Pentazocin und NaloxonOpioidSchwerwiegend

    Any individual who has failed the naloxone challenge test or has a positive urine screen for opioids [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • PethidinOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • Promethazin und CodeinOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • RemifentanilOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • TapentadolOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • TramadolOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

  • Tramadol und ParacetamolOpioidSchwerwiegend

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Fachinformation zu Naltrexon, Gegenanzeigen)

Mittelschwere Wechselwirkungen (3)

  • Etravirinantiretrovirales ArzneimittelMittelschwer

    Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (Fachinformation zu Etravirin, Arzneimittelwechselwirkungen)

  • LofexidinAlpha-Adrenozeptor-AgonistMittelschwer

    Oral Naltrexone : Concomitant use may reduce efficacy of oral naltrexone. (Fachinformation zu Lofexidin, Arzneimittelwechselwirkungen)

  • NalmefenOpioidantagonistMittelschwer

    Strongly consider recommending or prescribing an opioid reversal agent (e.g., naloxone, nalmefene) for the emergency treatment of opioid overdose (5.1) . (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

Geringfügige Erwähnungen (31)

  • AlkoholAlkoholGeringfügig

    Precipitation of Opioid Withdrawal : Opioid-dependent and opioid-using patients, including those being treated for alcohol dependence, should be opioid-free before starting naltrexone for extended-release injectable suspension treatment, and should notify healthcare providers of any recent opioid use. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • Azelastin und FluticasonAntihistaminikumGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • BeclometasonKortikosteroidGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • BetamethasonKortikosteroidGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • BudesonidKortikosteroidGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • Budesonid und FormoterolKortikosteroidGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • CiclesonidKortikosteroidGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • ClobetasolKortikosteroidGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • DeflazacortKortikosteroidGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • DesfluranAllgemeinanästhetikumGeringfügig

    The opioid therapy must be provided by individuals specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids, specifically the establishment and maintenance of a patent airway and assisted ventilation. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • DesonidKortikosteroidGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • DexamethasonKortikosteroidGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • EtomidatAllgemeinanästhetikumGeringfügig

    The opioid therapy must be provided by individuals specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids, specifically the establishment and maintenance of a patent airway and assisted ventilation. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • FludrocortisonKortikosteroidGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • FlunisolidKortikosteroidGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • FluocinonidKortikosteroidGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • FluticasonKortikosteroidGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • Fluticason und SalmeterolKortikosteroidGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • HalobetasolKortikosteroidGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • HydrocortisonKortikosteroidGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • IsofluranAllgemeinanästhetikumGeringfügig

    The opioid therapy must be provided by individuals specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids, specifically the establishment and maintenance of a patent airway and assisted ventilation. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • KetaminZNS-dämpfendes ArzneimittelGeringfügig

    The opioid therapy must be provided by individuals specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids, specifically the establishment and maintenance of a patent airway and assisted ventilation. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • MethohexitalBarbituratGeringfügig

    The opioid therapy must be provided by individuals specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids, specifically the establishment and maintenance of a patent airway and assisted ventilation. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • MethylprednisolonKortikosteroidGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • MometasonKortikosteroidGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • Olopatadin und MometasonAntihistaminikumGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • PrednisolonKortikosteroidGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • PrednisonKortikosteroidGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • PropofolZNS-dämpfendes ArzneimittelGeringfügig

    The opioid therapy must be provided by individuals specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids, specifically the establishment and maintenance of a patent airway and assisted ventilation. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • SevofluranAllgemeinanästhetikumGeringfügig

    The opioid therapy must be provided by individuals specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids, specifically the establishment and maintenance of a patent airway and assisted ventilation. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • TriamcinolonKortikosteroidGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

Keine relevante Wechselwirkung berichtet (3)

  • AcamprosatKeine Wechselwirkung

    The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed [ see Clinical Pharmacology ( 12.3 ) ]. (Fachinformation zu Acamprosat, Arzneimittelwechselwirkungen)

  • Elvitegravir, Cobicistat, Emtricitabin und Tenofovirantiretrovirales ArzneimittelKeine Wechselwirkung

    Narcotic Analgesics: buprenorphine/ naloxone ↑ buprenorphine ↑ norbuprenorphine ↓ naloxone No dosage adjustment of buprenorphine/naloxone is required upon coadministration with GENVOYA. (Fachinformation zu Elvitegravir, Cobicistat, Emtricitabin und Tenofovir, Arzneimittelwechselwirkungen)

  • Emtricitabin und Tenofovirantiretrovirales ArzneimittelKeine Wechselwirkung

    No clinically significant drug interactions have been either observed or are expected when DESCOVY is combined with the following drugs: buprenorphine, itraconazole, ketoconazole, lorazepam, methadone, midazolam, naloxone, norbuprenorphine, norgestimate/ethinyl estradiol, and sertraline. (Fachinformation zu Emtricitabin und Tenofovir, Arzneimittelwechselwirkungen)

Prüfen Sie Naltrexon gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.

Im Wechselwirkungscheck öffnen

Keine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.